top of page
CONNECT
Let science do the talking
HOME
SCIENCE
Immune Oncology
Acetate Metabolism
Runaway Immune Response
Vaccine Adjuvants
Neuroscience
RESEARCH
Current Programs
Pipeline
Academic Alliances
Licensing & Partnership
Our Publications
TEAM
Leadership
Advisors
NEWSROOM
CSR
CAREERS
CONTACT US
More
Use tab to navigate through the menu items.
O
ur
P
ipeline
Indication Target Mode of Action
Oncology
STING
Agonist
IND enabling
Inflammation
STING
Antagonist
Lead Generation stage
Oncology
ACSS2
Inhibitor
Candidate Selection stage
Oncology
TDO/IDO
Inhibitor
IND enabling stage
Oncology
HPK1
Inhibitor
Lead Generation stage
Lead Generation stage
Lead Generation
Feasibility
Candidate Selection
IND Enabling
bottom of page
